WUXI BIOLOGICS DL-,000025 Forum: Community User: Summer.76

Weiß oder hat einer Kursziele für die Firma ?

NOTICE OF EXTRAORDINARY GENERAL MEETING (will be held at the meeting room of Sheraton Shanghai Waigaoqiao Hotel, November 12, 2020 at 3:00 p.m.) https://doc.irasia.com/listco/hk/wuxibiologics/announcement/a201023.pdf PROPOSED SHARE SUBDIVISION AND NOTICE OF EXTRAORDINARY GENERAL MEETING https://doc.irasia.com/listco/hk/wuxibiologics/circulars/c201023.pdf FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON THURSDAY, NOVEMBER 12, 2020 https://doc.irasia.com/listco/hk/wuxibiologics/circulars/c201023a.pdf

Gutes Timing! Mal sehen, wie sich der beabsichtigte Split auswirken wird.

👌 Hatte erst gestern nachgelegt...

https://www.marketscreener.com/quote/stock/WUXI-BIOLOGICS-CAYMAN-I-37230806/news/WuXi-Biologics-Cayman-Shares-Soar-on-Upbeat-Revenue-Guidance-China-s-Vaccine-Progress-31579102/ ... The company's share price surge also came as Chinese authorities on Tuesday provided an upbeat update on the country's vaccine development, projecting annual production capacity to reach 610 million units by year-end.

WuXi Biologics (02269.HK) launches new strategy and benefits from the new crown project management expected to increase revenue by 50% next year http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1050203/popular-news An analyst meeting was held yesterday (20th) to update the company’s operations. The company’s management explained its new strategy "drug molecule". This is the company’s most recent Win more late-stage contracts than peers. The company’s management stated that due to multiple new coronavirus-related projects and its “drug molecule” strategy, the management expects that the company’s revenue in the second half of this year will grow by 40% year-on-year, and it is expected that revenue will grow by 50% in 2021, and will be in 2022 The annual growth target is set at 40%. According to the bank, WuXi Biologics has perfected its "drug molecule" strategy, and the backlog of orders growth is moving toward the bank's expectations, which is expected to reach 10.273 billion US dollars, which is a 101% increase so far this year. In addition, the company also signed a new coronavirus vaccine agreement worth up to 400 million U.S. dollars, indicating that the relevant data once again strengthened the bank's confidence in WuXi Bioenergy's recognition of global customers. According to the bank, under the new strategy, WuXi Biologics will have 10 pharmaceutical contract customized research and development manufacturing enterprises (CDMOs) by 2020 (providing multinational pharmaceutical companies and biotech companies with the process development and preparation of pharmaceuticals, especially innovative drugs). Project transfer is higher than the number of external projects added in all previous years. Of these 10 projects, 6 are in phase III clinical trials, and 1 is related to the new coronavirus, which indicates the recent revenue growth trend. The company's management pointed out that the newly established dual-strategy structure is based on WuXi's leading technology and industry capabilities. The bank is very optimistic about the potential synergy brought by the company's new strategic combination. Yamato believes that WuXi Biologics has a strong ability to deal with the new coronavirus pandemic, and pointed out that the company has added 72 new projects this year (62 in the first phase), setting a record in the company's history. It is worth noting that the company successfully signed another vaccine agreement worth up to 400 million US dollars. The total number of projects currently under preparation reaches 312, an increase of 25% over the year to date. Driven by newly added projects, especially more than 20 new coronavirus-related projects ($528 million have been signed and about US$500 million under discussion), it is estimated that the company’s outstanding service orders from the new crown virus project may be available. Reached $1 billion.

http://www.aastocks.com/en/stocks/news/aafn-con/now.1050230/latest-news Macquarie Lifts WUXI BIO (02269.HK) TP by 25% to $262.05, Seen as Sector Top Pick

G Sachs: WUXI BIO New Strategy Becomes Growth Driver; Mgmt Tweaks Up 21E Earing Growth Guidance http://www.aastocks.com/en/stocks/news/aafn-con/now.1050250/latest-news WUXI BIO (02269.HK) updated its operation position at an analyst meeting, Goldman Sachs mentioned in its report. At which, the management illustrated its latest strategy - "win-the-molecule" - for the first time, in hope of harvesting more market share by transferring projects from competitors. The broker believed the new strategy to become the company's future growth driver. In view of new strategy and more-than-expected contribution from Covid-19 related projects, the management hiked its 2021E earnings growth guidance to 50%+ YoY (from 40%+ previously).

https://bioprocessintl.com/bioprocess-insider/therapeutic-class/wuxi-cdmo-selection-the-last-barrier-to-adc-advancement/

WuXi Biologics steigt um über 4% und erreicht ein Rekordhoch https://finance.sina.cn/hkstock/sckxjfx/2020-10-12/detail-iivhuipp9154296.d.html?from=wap WuXi Biologics (02269.HK) stieg um mehr als 4% und erreichte ein Rekordhoch von 211,6 Hongkong-Dollar. Der Aktienkurs ist seit Ende März um mehr als 115% gestiegen.  ...

Antengene Announces Collaboration with WuXi Biologics to Advance the Development of Innovative Oncology Medicines https://www.prnewswire.com/news-releases/antengene-announces-collaboration-with-wuxi-biologics-to-advance-the-development-of-innovative-oncology-medicines-301149753.html

WuXi Biologics Unveils New Process Development and Testing Facility in King of Prussia, Pennsylvania https://www.wuxibiologics.com/wuxi-biologics-unveils-new-process-development-testing-facility-king-prussia-pennsylvania/

WuXi Biologics ist an fünf aufeinander folgenden Tagen um fast 15% gestiegen https://www.bastillepost.com/hongkong/article/7253630-ticker%e6%95%b8%e6%93%9a-%e7%99%be%e6%bf%9f%e7%a5%9e%e5%b7%9e%e4%ba%94%e9%80%a3%e5%8d%87-%e7%b4%af%e5%8d%87%e8%bf%9115/ WuXi Biologics (02269) erfreute sich erneut großer Beliebtheit, stieg an 5 aufeinanderfolgenden Tagen um 14,83% und erreichte einen Höchststand von 204,6 Yuan bei einem Umsatz von 650 Millionen Yuan. ... WuXi Biologics hat zuletzt angekündigt, dass es beabsichtigt, einen Aktiensplit auf der Grundlage von drei unterteilten Aktien für jede bestehende ausgegebene Aktie durchzuführen.  Nomura hat WuXi Biologics ein "Kauf"-Rating und einen Zielpreis von RMB213,1 gegeben und erklärt, die Gruppe könne ihren Marktanteil weiter ausbauen, doch die internationale Konkurrenz sei ein großes Problem. Wie die Bank mitteilte, verfügte die Gruppe Ende letzten Jahres über 43 integrierte Projekte in den Phasen 2 und 3, die in den nächsten drei bis sechs Jahren für die Markteinführung neuer Medikamente bereit sein könnten, und es wird erwartet, dass das Wachstum der Projekte in der letztgenannten Phase zur Steigerung der Rentabilität der Gruppe beitragen wird. Es wird erwartet, dass die kommerziellen Projekte bis Ende 2030 zu Einnahmen in Höhe von 54,3 Milliarden RMB beitragen werden, was 57% der Einnahmen der Gruppe ausmacht.

🍀💪

Bin auch dabei hoffen wir mal auf gute Gewinne uns allen ,die in Wuxi investiert 😜

The JP Morgan Asia Growth fund manager explains why she tries not to second-guess politics, why volatility is inevitable and the importance of teamwork. https://citywire.co.uk/wealth-manager/news/profile-inside-jpm-aaa-rated-joanna-kwoks-stunning-run/a1401817 ... ‘We invest in growth companies that can deliver superior returns for a long time,’ she says. ‘We are not trying to second-guess politics because it doesn’t add much value. We focus on finding the quality companies that continue to have superior performance.’ The fund is overweight technology and healthcare, allocating 24% and 23% of assets respectively, and also has big sectoral allocations to consumer discretionary (20%) and communications (16%). ... Kwok says selection is grounded in the house’s conviction in the continuing growth of regional consumption, and identifying quality companies able to meet that demand. ‘A lot of the companies that we like that are big and doing well domestically, but they won’t be widely held in the west,’ she says. ‘Names such as Samsung [her fourth-largest holding] are doing well internationally, are globally exposed, and we continue to like them, but we also like domestic ones.’ Open-access biology tech platform Wuxi Biologics, a 2.7% position, is one such example. Although leading in its field, it is not held in a significant number of mainstream funds. Its share price rocketed 140% in the 12 months to the end of August, contributing 2.2% to the fund’s performance. ...